Patients with hereditary haemorrhagic telangiectasia (HHT) who suffer from severe epistaxis (nosebleeds) or gastrointestinal bleeding may benefit from intravenous bevacizumab, according to a new study. In severe HHT, malformed blood vessels in the...
6 years ago